MedTrace Logo

Clinical Efficacy of Exosome in Degenerative Meniscal Injury

NCT05261360 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-04

No results posted yet for this study

Summary

Comparison of intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes with synovial fluid-derived mesenchymal stem cells on the same patient.

Conditions

  • Knee; Injury, Meniscus (Lateral) (Medial)
  • Meniscus Tear
  • Meniscus Lesion
  • Meniscus; Degeneration
  • Meniscus; Laceration
  • Meniscus Injury, Tibial
  • Knee Injuries
  • Knee Pain Swelling
  • Arthralgia

Interventions

DRUG

SF-MSC-EX

Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes

DRUG

SF-MSC

Intra-articular administration of synovial fluid-derived mesenchymal stem cells

Sponsors & Collaborators

  • The Scientific and Technological Research Council of Turkey

    collaborator OTHER

  • Eskisehir Osmangazi University

    lead OTHER

Principal Investigators

  • Ayla Eker Sarıboyacı, AssocProfDr. · Cell Therapy and Stem Cell Production Application and Research Center (ESTEM)

  • Onur Uysal, AssocProfDr. · Cell Therapy and Stem Cell Production Application and Research Center (ESTEM)

  • Ulukan İnan, ProfDr. · Eskisehir Osmangazi University Faculty of Medicine Department of Orthopedy and Traumatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2024-03-31
Completion
2025-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05261360 on ClinicalTrials.gov